Extraction and purification of a novel hemocyanin through implementation of new technologies.

Mikota Ltd正在寻求对拖鞋帽贝血液中的血蓝蛋白进行早期调查，这是一种入侵英国海岸的非本土物种。在成功鉴定了帽带中的血蓝蛋白并起草和测试了基本提取方案后，Mikota现在的目标是将这种血蓝蛋白的生产扩大到商业水平。除了扩大生产，我们还将专注于完善成品的储存方法，以保持血蓝蛋白的长期储存能力。这项工作是与卡迪夫大学合作进行的，他们的工作方案由Mark Young博士和Thomas Wirth教授领导。为了支持加的夫大学的工作，以及Mikota帮助年轻人为工作做准备，Mikota正在资助3名专业年级的学生进入加的夫大学。通过扩大这一过程的规模，Mikota将向英国提供一种新的可持续医用级别的血蓝蛋白，它来自当地的一种入侵物种，在抗癌、疫苗和免疫治疗市场上具有重要价值。

"Mikota Ltd is looking to build on early investigative work into hemocyanin from the blood of the slipper limpet, an invasive, non-native species to UK shores. Having successfully identified hemocyanin proteins in the limpets as well as drafted and tested a basic extraction protocol, Mikota now aims to scale up production of this hemocyanin to a commercial level. As well as scaling up production, we will focus on perfecting a storage method for the finished product that will preserve the viability of the hemocyanin for long term storage.This work is being undertaken in collaboration with Cardiff University, with their work packages being led by Dr Mark Young and Prof Thomas Wirth. In support of Cardiff University work, and Mikota's helping young people prepare for the work place, Mikota is funding 3 Professional Year students to be placed at Cardiff University.By scaling up this process Mikota will deliver a new sustainable medical grade hemocyanin sourced locally from an invasive species to the UK, that has significant value in the anticancer, vaccine and immunotherapy markets."